Literature DB >> 31107307

An overview of international cardiogenic shock guidelines and application in clinical practice.

Sean van Diepen1,2,3, Holger Thiele4.   

Abstract

PURPOSE OF REVIEW: In this review, we compare central differences in cardiogenic shock recommendations in international clinical practice guidelines, scientific statements, and the strength of the supporting evidence. Furthermore, we discuss their associations with adherence to guidelines in registry studies. RECENT
FINDINGS: The evidence base underpinning American Heart Association/American College of Cardiology's and European Society of Cardiology's recommendations for an early invasive approach is relatively strong, but adherence to these recommendations is poor in registry and population-based studies. There is little evidence supporting the use of temporary mechanical circulatory support or pulmonary arterial catherization in cardiogenic shock, and international guidelines provide weak and conflicting recommendations, yet studies show mechanical circulatory support use is rising exponentially while pulmonary arterial catherization use remains low. Guidelines provide conflicting information on the optimal first-line vasoactive agent and norepinephrine remains the most widely used agent.
SUMMARY: There are some inconsistencies between individual guideline recommendations, but there are no consistent associations between the strength of underlying evidence, weight of guideline recommendations, and adherence to guidelines in clinical practice. Improved knowledge translation of recommendations with a strong evidence base, together with research efforts to address priority cardiogenic shock research needs, could serve-to-harmonize recommendations and improve patient outcomes.

Entities:  

Mesh:

Year:  2019        PMID: 31107307     DOI: 10.1097/MCC.0000000000000624

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  4 in total

Review 1.  Vasopressor therapy in critically ill patients with shock.

Authors:  James A Russell
Journal:  Intensive Care Med       Date:  2019-10-23       Impact factor: 17.440

2.  Vasoactive pharmacologic therapy in cardiogenic shock: a critical review.

Authors:  Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam
Journal:  J Drug Assess       Date:  2021-07-20

3.  Budget Impact Associated with the Introduction of the Impella 5.0® Mechanical Circulatory Support Device for Cardiogenic Shock in France.

Authors:  Alexandre Le Guyader; Mathieu Pernot; Clément Delmas; Stéphane Roze; Isabelle Fau; Erwan Flecher; Guillaume Lebreton
Journal:  Clinicoecon Outcomes Res       Date:  2021-01-19

4.  Budget Impact Analysis of Impella CP® Utilization in the Management of Cardiogenic Shock in France: A Health Economic Analysis.

Authors:  Clément Delmas; Mathieu Pernot; Alexandre Le Guyader; Romain Joret; Stéphane Roze; Guillaume Lebreton
Journal:  Adv Ther       Date:  2022-01-23       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.